Roivant posts lower than expected Q2 operating loss on lower R&D espenses
Overview
Switzerland biopharma's Q2 net product revenue was $31.0 mln, driven by LISRAYA launch
Income from operations for Q2 beat analyst expectations
Company repurchased 2.1 mln shares for $72.5 mln during the quarter
Outlook
Roivant expects cash runway into profitability, supported by $4.2 bln cash as of Sept 30, 2026
Company plans sNDA filing for brepocitinib in NIU in H1 2027
Immunovant to meet with FDA in 2026 on IMVT-1402 registrational path in D2T RA
Result Drivers
LISRAYA LAUNCH - Q2 revenue driven by $31.0 mln in net product revenue from LISRAYA's first 5 weeks on the market, reflecting early patient and prescriber demand, per CEO Matt Gline
HIGHER SG&A COSTS - Selling, general and administrative expenses rose $11.0 mln year-over-year, mainly due to costs related to the commercial launch of LISRAYA
LOWER R&D EXPENSES - R&D expenses fell $18.8 mln year-over-year, mainly due to reduced personnel and program-specific costs, including lower spending on discontinued and winding-down studies
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | $30.97 mln | ||
Q2 Net Loss | $137.21 mln | ||
Q2 Income From Operations | Beat | -$268.05 mln | -$336.33 mln (10 Analysts) |
Q2 Loss Per Basic Share | $0.27 | ||
Q2 Operating Expenses | $303.17 mln |
Reuters Recommended Reads
Nov 6 - CG Oncology Q3 net loss widens on higher R&D costs
Nov 7 - Trial failures of Novartis, Novo Nordisk heart drugs leave experts guessing
Nov 6 - Minerva Neurosciences posts Q3 profit on non-cash warrant gain
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)